FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035826098> ?p ?o ?g. }

• W3035826098 abstract "Low‐dose afatinib maintenance treatment among patients with EGFR‐mutated NSCLC achieved long‐time to treatment failure with fewer treatment‐related AEs without detracting from the therapeutic efficacy. This modified regimen represents a practical usage that balances effectiveness and safety. Although afatinib is an effective therapy for patients with EGFR‐mutated non‐small cell lung cancer (NSCLC), drug‐related adverse events (AEs) have often necessitated dose reductions. In a post hoc analysis of the LUX‐Lung 3 and 6 trials, there was no difference in median progression‐free survival (PFS) between patients who had the dose of afatinib reduced and those who did not. We thus evaluated the efficacy and tolerability of low‐dose afatinib maintenance treatment among patients with NSCLC harboring EGFR mutations who had not been previously treated. Eligible patients received afatinib 40 mg orally once daily. When prescribed grade ≥ 2 AEs, rash of grade ≥ 3, or unacceptable toxicity occurred, the afatinib dose was reduced from 40 to 30 mg and if needed from 30 to 20 mg. The primary endpoint was the 1‐year PFS rate. Secondary endpoints were PFS, overall response rate (ORR), and toxicity. Among 30 patients, 93% had adenocarcinoma, 53% had exon 19 deletion, 37% had L858R, and 10% had minor mutations. The 1‐year PFS rate was 50% (95% confidence interval [CI], 31.3–66.1) and the median PFS was 11.8 months (95% CI, 7.1–21.4). The incidence rate of grade ≥ 3 toxicities was 57%, including elevated aspartate aminotransferase/alanine aminotransferase level (13%), diarrhea (10%), and paronychia (10%). Low‐dose afatinib maintenance treatment reduced treatment‐related AEs without detracting from the therapeutic efficacy." @default.
• W3035826098 created "2020-06-25" @default.
• W3035826098 creator A5000569963 @default.
• W3035826098 creator A5003529714 @default.
• W3035826098 creator A5007607688 @default.
• W3035826098 creator A5009536702 @default.
• W3035826098 creator A5015201626 @default.
• W3035826098 creator A5028588267 @default.
• W3035826098 creator A5032063684 @default.
• W3035826098 creator A5040162534 @default.
• W3035826098 creator A5078476949 @default.
• W3035826098 creator A5080846994 @default.
• W3035826098 date "2020-07-07" @default.
• W3035826098 modified "2023-10-16" @default.
• W3035826098 title "Phase II Study of Low‐Dose Afatinib Maintenance Treatment Among Patients with EGFR ‐Mutated Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 ( NJLCG1601 )" @default.
• W3035826098 cites W1574226582 @default.
• W3035826098 cites W2056659899 @default.
• W3035826098 cites W2063391304 @default.
• W3035826098 cites W2096198395 @default.
• W3035826098 cites W2129360604 @default.
• W3035826098 cites W2132157071 @default.
• W3035826098 cites W2132870547 @default.
• W3035826098 cites W2138851777 @default.
• W3035826098 cites W2139804581 @default.
• W3035826098 cites W2171139285 @default.
• W3035826098 cites W2508069933 @default.
• W3035826098 cites W2512922897 @default.
• W3035826098 cites W2587420003 @default.
• W3035826098 cites W2896248377 @default.
• W3035826098 cites W2990041408 @default.
• W3035826098 doi "https://doi.org/10.1634/theoncologist.2020-0545" @default.
• W3035826098 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7543297" @default.
• W3035826098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32559335" @default.
• W3035826098 hasPublicationYear "2020" @default.
• W3035826098 type Work @default.
• W3035826098 sameAs 3035826098 @default.
• W3035826098 citedByCount "4" @default.
• W3035826098 countsByYear W30358260982021 @default.
• W3035826098 countsByYear W30358260982022 @default.
• W3035826098 countsByYear W30358260982023 @default.
• W3035826098 crossrefType "journal-article" @default.
• W3035826098 hasAuthorship W3035826098A5000569963 @default.
• W3035826098 hasAuthorship W3035826098A5003529714 @default.
• W3035826098 hasAuthorship W3035826098A5007607688 @default.
• W3035826098 hasAuthorship W3035826098A5009536702 @default.
• W3035826098 hasAuthorship W3035826098A5015201626 @default.
• W3035826098 hasAuthorship W3035826098A5028588267 @default.
• W3035826098 hasAuthorship W3035826098A5032063684 @default.
• W3035826098 hasAuthorship W3035826098A5040162534 @default.
• W3035826098 hasAuthorship W3035826098A5078476949 @default.
• W3035826098 hasAuthorship W3035826098A5080846994 @default.
• W3035826098 hasBestOaLocation W30358260981 @default.
• W3035826098 hasConcept C121608353 @default.
• W3035826098 hasConcept C126322002 @default.
• W3035826098 hasConcept C141071460 @default.
• W3035826098 hasConcept C143998085 @default.
• W3035826098 hasConcept C197934379 @default.
• W3035826098 hasConcept C203092338 @default.
• W3035826098 hasConcept C2776256026 @default.
• W3035826098 hasConcept C2778087573 @default.
• W3035826098 hasConcept C2778375690 @default.
• W3035826098 hasConcept C2778570526 @default.
• W3035826098 hasConcept C2779438470 @default.
• W3035826098 hasConcept C2780586478 @default.
• W3035826098 hasConcept C2781413609 @default.
• W3035826098 hasConcept C29730261 @default.
• W3035826098 hasConcept C535046627 @default.
• W3035826098 hasConcept C71924100 @default.
• W3035826098 hasConcept C90924648 @default.
• W3035826098 hasConceptScore W3035826098C121608353 @default.
• W3035826098 hasConceptScore W3035826098C126322002 @default.
• W3035826098 hasConceptScore W3035826098C141071460 @default.
• W3035826098 hasConceptScore W3035826098C143998085 @default.
• W3035826098 hasConceptScore W3035826098C197934379 @default.
• W3035826098 hasConceptScore W3035826098C203092338 @default.
• W3035826098 hasConceptScore W3035826098C2776256026 @default.
• W3035826098 hasConceptScore W3035826098C2778087573 @default.
• W3035826098 hasConceptScore W3035826098C2778375690 @default.
• W3035826098 hasConceptScore W3035826098C2778570526 @default.
• W3035826098 hasConceptScore W3035826098C2779438470 @default.
• W3035826098 hasConceptScore W3035826098C2780586478 @default.
• W3035826098 hasConceptScore W3035826098C2781413609 @default.
• W3035826098 hasConceptScore W3035826098C29730261 @default.
• W3035826098 hasConceptScore W3035826098C535046627 @default.
• W3035826098 hasConceptScore W3035826098C71924100 @default.
• W3035826098 hasConceptScore W3035826098C90924648 @default.
• W3035826098 hasIssue "10" @default.
• W3035826098 hasLocation W30358260981 @default.
• W3035826098 hasLocation W30358260982 @default.
• W3035826098 hasLocation W30358260983 @default.
• W3035826098 hasOpenAccess W3035826098 @default.
• W3035826098 hasPrimaryLocation W30358260981 @default.
• W3035826098 hasRelatedWork W2137432312 @default.
• W3035826098 hasRelatedWork W2281121233 @default.
• W3035826098 hasRelatedWork W2408182535 @default.
• W3035826098 hasRelatedWork W2568481827 @default.
• W3035826098 hasRelatedWork W2570408608 @default.
• W3035826098 hasRelatedWork W2734557114 @default.
• W3035826098 hasRelatedWork W2792068284 @default.
• W3035826098 hasRelatedWork W2888534976 @default.

• next